Evidence map›Paper›PMID 41279980›Full record

ArticlebioRxiv : the preprint server for biology2025

Iterative immunogen optimization to focus immune responses on a conserved, subdominant viral epitope.

Daniel J Marston, Akiko Watanabe, A Brenda Kapingidza, Caitlin Harris, Elizabeth Van Itallie, Kapil Devkota, Jayani Christopher, Peiying Liu, Beena Pun, Brianna Rhodes and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Daniel J MarstonDuke Human Vaccine Institute, Duke University, Durham, NC.
Akiko WatanabeDepartment of Integrative Immunology, Duke University, Durham, NC, USA.
A Brenda KapingidzaDuke Human Vaccine Institute, Duke University, Durham, NC.
Caitlin HarrisDuke Human Vaccine Institute, Duke University, Durham, NC.
Elizabeth Van ItallieDuke Human Vaccine Institute, Duke University, Durham, NC.
Kapil DevkotaDepartment of Cell Biology, Duke University, Durham, NC.
Jayani ChristopherDuke Human Vaccine Institute, Duke University, Durham, NC.
Peiying LiuDepartment of Integrative Immunology, Duke University, Durham, NC, USA.
Beena PunDepartment of Integrative Immunology, Duke University, Durham, NC, USA.
Brianna RhodesDuke Human Vaccine Institute, Duke University, Durham, NC.
McKenzie FrazierDuke Human Vaccine Institute, Duke University, Durham, NC.
Kaitlyn WintersDuke University, Durham, NC.
Heman BurreDuke University, Durham, NC.
Pranav KannanDuke University, Durham, NC.
Xiaoe LiangDepartment of Integrative Immunology, Duke University, Durham, NC, USA.
Garnett KelsoeDuke Human Vaccine Institute, Duke University, Durham, NC.
Kevin WieheDuke Human Vaccine Institute, Duke University, Durham, NC.
Rohit SinghDepartment of Cell Biology, Duke University, Durham, NC.
Daniel WrappDuke Human Vaccine Institute, Duke University, Durham, NC.
Masayuki KuraokaDepartment of Integrative Immunology, Duke University, Durham, NC, USA.
Mihai L AzoiteiDuke Human Vaccine Institute, Duke University, Durham, NC.

Funding

Model and Data Sharing CoreU54AI191253 · NIAID · DUKE UNIVERSITY · PI Cliburn C Chan · 2025 to 2026
$16.4M
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer InterfaceR01AI155804 · NIAID · DUKE UNIVERSITY · PI AZOITEI, MIHAI LUCHIAN · 2021 to 2024
$3.9M
Multiscale Modeling of Influenza Neutralizing Antibody and Fc Effector BiologyU01AI186999 · NIAID · DUKE UNIVERSITY · PI Cliburn C Chan, Roger Keith Reeves · 2025 to 2026
$2.1M
NIAID NIH HHS R01 AI155804NIAID NIH HHS U01 AI186999NIAID NIH HHS U54 AI191253
6 · The paper itself

Abstract

Designing effective vaccination strategies against genetically diverse viruses, such as HIV or influenza, is hindered by the ability of these pathogens to mutate and readily evade immune control. While these viruses contain conserved regions that cannot easily mutate without affecting viral fitness, these sites are subdominant, meaning that they are not the primary target of immune responses elicited by natural infection or current vaccines. Here, we integrated recent advances in machine learning methods for protein structure prediction and design to engineer protein immunogens that focus immune responses on a conserved, subdominant HA epitope targeted by broadly cross-reactive influenza antibodies. Iterating between computation-guided optimization and

Identifiers

PMID41279980
PMCPMC12637436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.